Abbott recognized MitraClip and TriClip TEER therapies in ESC/EACTS valvular heart disease guidelines
Public source
Publisher name
Public post
What is a defining moment for heart failure patients? At #ESCCongress, new Heart Failure Guidelines further emphasize the importance of identifying and managing structur…
Company
Abbott
- Industry
- Hospitals and Health Care
- Location
- Abbott Park, US
- Company size
- 10,001+ employees
About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritional and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottCareers, on Instagram @AbbottGlobal, and on X @AbbottNews. We invite you to explore opportunities at Abbott, to see if your talents and career aspirations may fit with our openings. An equal opportunity employer, Abbott welcomes and encourages diversity in our workforce. Terms of Use: https://www.abbott.com/social-media-terms-of-use.html Privacy Policy: https://abbo.tt/privacy
See moreDiscover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Edwards Lifesciences
Edwards Lifesciences published the 2026 ESC Heart Failure Guidelines detailing updates for transcatheter mitral and tricuspid therapies.
Research & Knowledge
Philips
Philips published primary results showing that implementation of the RECTIFY intervention increased guideline recommended therapy of hardware removal for patients with CIED infections.
Research & Knowledge
Getinge
Getinge published recent studies demonstrating that prophylactic IABP support provides crucial hemodynamic stabilization in patients with advanced heart failure undergoing high-risk structural heart procedures such as MitraClip and TAVI.
Research & Knowledge
Medtronic
Medtronic published the CLIP-IT post-market study showing that the Penditure™ LAA exclusion system achieved a 100% rate of successful exclusion of the left atrium from the heart defined as the absence of residual communication between the left atrium and the LAA.
Research & Knowledge
AtriCure, Inc.